|93.08||+0.4700||+0.51%||Vol 365.45K||1Y Perf 44.95%|
|Apr 13th, 2021 16:00 DELAYED|
|- -||- -%|
|Target Price||105.27||Analyst Rating||Strong Buy 1.32|
|Potential %||13.10||Finscreener Ranking||★★★★★ 66.01|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★★★★ 66.94|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★★★ 87.33|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Market Cap||5.39B||Earnings Rating||Sell|
|Price Range Ratio 52W %||53.27||Earnings Date||5th May 2021|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||5th May 2021|
|Estimated EPS Next Report||-1.72|
|EPS Growth Next 5 Years %||34.00|
|Avg. Weekly Volume||318.44K|
|Avg. Monthly Volume||367.08K|
|Avg. Quarterly Volume||416.96K|
Blueprint Medicines Corporation (NASDAQ: BPMC) stock closed at 92.61 per share at the end of the most recent trading day (a -1.65% change compared to the prior day closing price) with a volume of 455.17K shares and market capitalization of 5.39B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 429 people. Blueprint Medicines Corporation CEO is Jeffrey W. Albers.
The one-year performance of Blueprint Medicines Corporation stock is 44.95%, while year-to-date (YTD) performance is -17.42%. BPMC stock has a five-year performance of 363.05%. Its 52-week range is between 56 and 125.61, which gives BPMC stock a 52-week price range ratio of 53.27%
Blueprint Medicines Corporation currently has a PE ratio of 18.20, a price-to-book (PB) ratio of 3.71, a price-to-sale (PS) ratio of 6.82, a price to cashflow ratio of 13.70, a PEG ratio of 2.32, a ROA of 25.22%, a ROC of 32.91% and a ROE of 31.78%. The company’s profit margin is 55.51%, its EBITDA margin is 40.90%, and its revenue ttm is $787.57 Million , which makes it $13.59 revenue per share.
Of the last four earnings reports from Blueprint Medicines Corporation, there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-1.72 for the next earnings report. Blueprint Medicines Corporation’s next earnings report date is 05th May 2021.
The consensus rating of Wall Street analysts for Blueprint Medicines Corporation is Strong Buy (1.32), with a target price of $105.27, which is +13.10% compared to the current price. The earnings rating for Blueprint Medicines Corporation stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Blueprint Medicines Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Blueprint Medicines Corporation has a Sell technical analysis rating based on Technical Indicators (ADX : 8.05, ATR14 : 5.65, CCI20 : -82.07, Chaikin Money Flow : 0.01, MACD : -1.94, Money Flow Index : 40.81, ROC : -2.22, RSI : 46.32, STOCH (14,3) : 22.62, STOCH RSI : 0.79, UO : 43.69, Williams %R : -77.38), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Blueprint Medicines Corporation in the last 12-months were: Alexis A. Borisy (Option Excercise at a value of $0), Anthony L. Boral (Option Excercise at a value of $634 741), Anthony L. Boral (Sold 40 000 shares of value $3 601 194 ), Ariel Hurley (Option Excercise at a value of $28 952), Ariel Hurley (Sold 9 957 shares of value $936 773 ), Charles A. Rowland (Option Excercise at a value of $307 653), Charles A. Rowland (Sold 20 909 shares of value $2 274 309 ), Christina Rossi (Sold 1 704 shares of value $152 313 ), Christopher K. Murray (Sold 1 210 shares of value $104 984 ), Daniel S. Lynch (Option Excercise at a value of $0), Debra Durso-Bumpus (Option Excercise at a value of $196 410), Debra Durso-Bumpus (Sold 8 393 shares of value $690 036 ), George D. Demetri (Option Excercise at a value of $0), George D. Demetri (Sold 2 462 shares of value $229 850 ), Jeffrey W. Albers (Option Excercise at a value of $704 000), Jeffrey W. Albers (Sold 88 886 shares of value $7 546 255 ), Kathryn Haviland (Option Excercise at a value of $582 653), Kathryn Haviland (Sold 19 838 shares of value $1 934 526 ), Lonnel Coats (Option Excercise at a value of $0), Lynn Seely (Option Excercise at a value of $0), Marion Dorsch (Option Excercise at a value of $964 044), Marion Dorsch (Sold 25 978 shares of value $2 533 400 ), Mark A. Goldberg (Option Excercise at a value of $827 229), Mark A. Goldberg (Sold 32 727 shares of value $3 681 795 ), Michael Landsittel (Sold 1 507 shares of value $130 749 ), Nicholas Lydon (Option Excercise at a value of $0), Nicholas Lydon (Sold 97 413 shares of value $7 953 846 ), Tracey McCain (Sold 1 893 shares of value $164 242 )
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.